Life-changing treatments for disorders of the immune system

Read More

Cyxone – an innovative clinical-stage biotech company

Cyxone develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. With three unique programs, Cyxone is well positioned to deliver substantial benefits for patients, the health care system as well as for its shareholders.

Our Drug Projects

Rheumatoid Arthritis (Rabeximod)

A unique mechanism-of-action combined with a convenient oral administration and a beneficial tolerability profile

Read More

Covid-19 (Rabeximod)

Inhibits the release of multiple cytokines without suppressing the general immune system

Read More

Multiple sclerosis (T20K)

Acts to stop or slow down the progression of multiple sclerosis

Read More

CEO Tara Heitner comments

We look forward to a productive year with accelerated progress. We are working intensively with the study centers in the Covid-19 trial to ensure a swift inclusion process and successful study completion. We will soon finalize development plans for Rabeximod in rheumatoid arthritis and initiate start-up activities for the trial later in the year. I will do my utmost to ensure that Cyxone can take further leaps forward in the coming year, all in the interest of providing patients with better treatments and at the same time enhancing shareholder value.

Read More